Drugs / Calaspargase
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06533748 Background | Jan 2025 → May 2028 expected | lymphoblastic lymphoma, precursor B-cell acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calaspargase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533748 ↗ |
| Route | Intravenous | “1 dose of daunorubicin IV, 1 dose of calaspargase IV” NCT06533748 ↗ |